secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001178913-24-001681
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio Q1 net loss $2.0M; cash $9.2M; FDA catalyst path for EB613
---------------------------------------------------------------------

- Q1 net loss $2.0M ($0.05 per share) vs $2.2M ($0.08) in Q1 2023.
- Cash $9.2M at March 31, 2024; runway into Q3 2025.
- R&D expenses $0.7M (down from $0.9M); G&A flat at $1.3M.
- FDA to rule on BMD as surrogate for fractures within 10 months – key catalyst for EB613 Phase 3.
- Oral GLP-2 tablets showed 10-fold higher plasma exposure vs teduglutide; OXM PK data expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/0001178913-24-001681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/zk2431441.htm
  HTML page:      https://secwatch.observer/filing/0001178913-24-001681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer